New Analysis Highlights Function of Life-style Elements, New Treatment Methods in Cancer Care

ALEXANDRIA, Va. – The world oncology group will collect in Chicago and on-line to debate the most recent cutting-edge most cancers analysis on the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Some of probably the most vital advances on this 12 months’s Press Program, protecting a variety of matters together with the impression of way of life components on most cancers outcomes, next-generation immunotherapies for hard-to-treat cancers, novel therapy methods for optimizing affected person care, and extra.
 
The 2026 ASCO Annual Meeting will happen May 29-June 2 in Chicago and on-line and complement Dr. Eric Small’s Presidential theme, “The Science and Practice of Translation: Improving Cancer Outcomes Worldwide.” 

More than 7,000 abstracts will probably be introduced or printed as a part of the 2026 ASCO Annual Meeting. ASCO will publish the common abstracts on Thursday, May 21, at 5:00 PM (ET) on asco.org/abstracts. Late-Breaking Abstracts (LBAs), together with Plenary abstracts, will probably be launched at 7:00 AM (CT)/8:00 AM (ET) on their day of scientific presentation on the Meeting.

Download a copy of the press briefing schedule
 
EMBARGOED PRE-MEETING PRESS BRIEFING (VIRTUAL EVENT) – Monday, May 18, 5:30-7:00 PM (ET)
For credentialed media, an embargoed digital press briefing will probably be held previous to the May 21 launch of standard abstracts, that includes the next research. The embargo on these research will raise on Thursday, May 21 at 5:00 PM (ET):

• Effects of short-term fasting in comparison with free eating regimen in ovarian most cancers sufferers: Results from a two-arm pilot randomized trial (Abstract 5517)
• Can GLP-1 receptor agonists mitigate most cancers development?: A propensity-matched evaluation throughout seven strong tumors (Abstract 3143)
• YOCAS yoga, temper disturbance, and insomnia: A URCC NCORP RB nationwide, part III, randomized, managed trial with most cancers survivors (Abstract 12004)
• Effect of a weight reduction intervention on high quality of life and signs in ladies with breast most cancers: Results from the Breast Cancer Weight Loss (BWEL) trial (Abstract 12010)
• Cognitive results of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized medical trial from the Alliance for Clinical Trials in Oncology (Abstract 5005)

EMBARGOED PRE-MEETING PRESS BRIEFING (VIRTUAL EVENT) – Tuesday, May 26, 3:30-5:00 PM (ET)
Several Late-Breaking Abstracts (LBAs) being introduced on Saturday, May 30, on the Meeting will probably be mentioned in an embargoed digital press briefing for credentialed media on May 26. The embargo will raise on these research on Saturday, May 30 at 7:00 AM (CT)/8:00 AM (ET):

• Omission of completion axillary dissection in sufferers with breast most cancers and sentinel lymph node macrometastases: Overall survival and patient-reported arm morbidity from the randomized SENOMAC trial (Abstract LBA503)
• NHS-Galleri: Primary outcomes from a randomised managed trial to evaluate the medical utility of a multi-cancer early detection check in inhabitants screening (Abstract LBA100)
• frontMIND: Phase 3 research of tafasitamab plus lenalidomide and R-CHOP for sufferers with newly recognized diffuse massive B-cell lymphoma (Abstract LBA7000)
• Final outcomes of a randomized, managed, part 3 trial evaluating resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for therapy of newly recognized mind metastases (Abstract LBA2000)

EMBARGOED ONSITE PRESS BRIEFING – Saturday, May 30, 8:00-9:30 AM CT/9:00-10:30 AM ET
Two press briefings will probably be held onsite in the course of the Annual Meeting and can spotlight LBAs being introduced in the course of the assembly. The press briefings will probably be held in particular person and obtainable just about through Zoom for credentialed reporters protecting the Meeting remotely. The first of those briefings will happen on Saturday, May 30. The embargo will raise on these LBAs on Sunday, May 31 at 7:00 AM (CT)/8:00 AM (ET):

• Final evaluation of PROTEUS, a part 3 randomized, double-blind, placebo–managed research of perioperative (neoadjuvant and adjuvant) apalutamide (APA) plus androgen deprivation remedy (ADT) versus ADT with radical prostatectomy (RP) in males with high-risk localized prostate most cancers (HRLPC) (Abstract LBA1)
• SARC041: A part 3 randomized double-blind research of abemaciclib versus placebo in sufferers with superior dedifferentiated liposarcoma (Abstract LBA2)
• Event-Free Survival with Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC: Primary Results of the Phase 3 LIBRETTO-432 Trial (Abstract LBA3)
• Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in beforehand untreated superior squamous non–small cell lung most cancers: Overall survival outcomes of the part 3 HARMONi-6 trial (Abstract LBA4)
• Daraxonrasib, a RAS(ON) multi-selective inhibitor, vs chemotherapy in beforehand handled sufferers with metastatic pancreatic adenocarcinoma: Primary evaluation from the part 3 RASolute 302 research (Abstract LBA5)
• Ultra-Low-Dose Immunotherapy Plus Oral Metronomic Chemotherapy Versus Paclitaxel-Carboplatin in Platinum-Sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Randomized Phase III Trial (Abstract LBA6007)

EMBARGOED ONSITE PRESS BRIEFING  – Sunday, May 31, 8:00-9:30 AM CT/9:00-10:30 AM ET
The second onsite press briefing will happen on Sunday, May 31. The embargo will raise on these LBAs on both Monday, June 1, or Tuesday, June 2 at 7:00 AM (CT)/8:00 AM (ET):

• SUPPORT+ digital self‑administration and medical assist for superior most cancers: A randomized managed trial (Abstract LBA12008)
  Embargo lifts Monday, June 1 at 7:00 AM (CT)/8:00 AM (ET)
• Efficacy and security outcomes from EMERALD-3: A part 3, randomized research of tremelimumab plus durvalumab with or with out lenvatinib mixed with transarterial chemoembolization in members with embolization-eligible unresectable hepatocellular carcinoma (Abstract LBA4000)
  Embargo lifts Monday, June 1 at 7:00 AM (CT)/8:00 AM (ET)
• Progression-free survival after subsequent line of therapy and subsequent therapies within the ASCENT-04 research of members with beforehand untreated PD-L1+ metastatic triple-negative breast most cancers handled with sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembro (Abstract LBA1000)
  Embargo lifts Tuesday, June 2 at 7:00 AM (CT)/8:00 AM (ET)

All press briefings can even be recorded and made obtainable to credentialed reporters for a interval of seven days following the briefing in ASCO’s Media Headquarters.

ADDITIONAL STUDIES OF NOTE 
The following research will probably be included within the official ASCO Tip Sheet, a quick abstract of extra noteworthy analysis. The Tip Sheet will probably be despatched to credentialed reporters forward of the Meeting and can embrace extra feedback from the lead authors and ASCO consultants.

The embargo will raise Thursday, May 21, at 5:00 PM (ET) for the next research:

• Overall survival subgroup analyses for prior taxane use within the part 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in sufferers with platinum-resistant ovarian most cancers (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023) (Abstract 5503)
• Structured train program following adjuvant chemotherapy for colon most cancers: A price-utility evaluation of the CHALLENGE trial (Abstract 3507)
• Efficacy of YES, an mHealth intervention for adolescent and younger adults with breast most cancers, to deal with AYA survivorship issues (Abstract 12009)
• Prevalence of symptomatic skeletal occasions with diminished denosumab dose density (each 12 weeks versus each 4 weeks): A randomized part III non-inferiority trial SAKK 96/12 REDUSE (Abstract 1004)
• Phase 3 trial of trastuzumab rezetecan vs normal of look after chemotherapy-refractory, HER2-positive, superior colorectal most cancers (Abstract 3505)
• Efficacy and security of giredestrant in sufferers with estrogen receptor–constructive, HER2-negative early breast most cancers within the part III lidERA BC medical trial: Results by menopausal standing (Abstract 502)
• GLP-1 receptor agonists for main prevention of breast most cancers in high-risk ladies: An actual-world evaluation of efficacy and security (Abstract 10520)
• Digital well being intervention for comorbid insomnia and neurocognitive impairment in grownup survivors of childhood most cancers: Results from a randomized medical trial (Abstract 10003)
• Real-world therapy patterns and mortality related to GLP1-RAs in breast most cancers sufferers (Abstract 629)
• Association of GLP-1 agonists with breast most cancers incidence in ladies (Abstract 10506)
• Progression-free survival after subsequent line of therapy and subsequent therapies within the ASCENT-03 research of members with beforehand untreated metastatic triple-negative breast most cancers handled with sacituzumab govitecan vs chemotherapy (Abstract 1001)
• Izalontamab brengitecan versus chemotherapy in sufferers with recurrent or metastatic esophageal squamous cell carcinoma: A multicenter, randomized, open-label, part III research (Abstract 4008)
• First outcomes from the OPTIMA part III randomized non-inferiority trial of test-directed chemotherapy in sufferers with excessive medical threat ER-positive HER2-negative early breast most cancers (Abstract 500)
• MajesTEC-9: A part 3 randomized research of teclistamab monotherapy vs investigator’s selection of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in sufferers (pts) with relapsed refractory a number of myeloma (Abtract 7507)

The embargo will raise Friday, May 29 at 7:00 AM (CT)/8:00 AM (ET) for the next research:

• Mezigdomide, carfilzomib, and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory a number of myeloma: Results from the part 3 SUCCESSOR-2 trial (Abstract LBA7506)

The embargo will raise Saturday, May 30 at 7:00 AM (CT)/8:00 AM (ET) for the next research:

• First interim evaluation of SWOG S1823: Operating traits of circulating microRNA 371a-3p in predicting lively germ cell malignancy in sufferers with early stage testicular most cancers (Abstract LBA5003)
• Efficacy and Safety of Asandeutertinib versus Osimertinib as First-line Treatment in EGFR-Mutated NSCLC Patients with Brain Metastases: Interim Analysis of an Open-Label, Multicenter, Randomized, Pivotal Phase II Study (ESAONA) (Abstract LBA2007)
• TALAPRO-3: Talazoparib + enzalutamide in contrast with placebo + ENZA for the therapy of sufferers with metastatic castration-sensitive prostate most cancers harboring homologous recombination restore gene alterations (Abstract LBA5007)

The embargo will raise Sunday, May 31 at 7:00 AM (CT)/8:00 AM (ET) for the next research:

• Early outcomes of COMPPARE, a potential comparability of outcomes with proton and photon radiation in prostate most cancers (Abstract LBA5012)

The embargo will raise Monday, June 1 at 7:00 AM (CT)/8:00 AM (ET) for the next research:

• Darovasertib together with crizotinib versus investigator’s selection as first-line therapy for sufferers with HLA-A2–damaging metastatic uveal melanoma: Results from the part 2/3 OptimUM-02 research (Abstract LBA9503)

The embargo will raise Tuesday, June 2 at 7:00 AM (CT)/8:00 AM (ET) for the next research:

• Izalontamab Brengitecan Versus Physician’s Choice of Chemotherapy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer: A Randomized Phase III Study (Abstract LBA1003)
• First-line camizestrant for emergent ESR1 mutations in superior breast most cancers: Final progression-free survival 2from the Phase III SERENA-6 trial (Abstract LBA1007)
• Giredestrant + palbociclib vs letrozole + PALBO as first-line remedy in sufferers with estrogen receptor–constructive, HER2-negative regionally superior or metastatic breast most cancers: Primary evaluation of the part III persevERA BC trial (Abstract LBA1006)

MEDIA RESOURCES 
 
Media registration: To take part within the Annual Meeting press briefings and/or register to attend the Meeting in particular person in Chicago, please go to ASCO’s Media Headquarters at https://mediahq.asco.org. Step-by-step directions can be found online. 
 
Requests for media credentials have to be submitted on-line by ASCO’s Media Headquarters no later than Wednesday, May 13, to take part within the pre-meeting press briefing on May 18. Pre-registration is required for on-site attendance and should even be requested by this date. 
 
Annual Meeting Media Resource Center: Visit asco.org/AMMRC for press releases, the press briefing schedule, details about onsite press services, and the Virtual Press Room (a web-based repository of company and institutional press supplies from third-party organizations).

### 

About ASCO:
Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO^®) is dedicated to the precept that data conquers most cancers. Together with the Association for Clinical Oncology, ASCO represents greater than 50,000 oncology professionals who look after folks residing with most cancers. Through analysis, training, and promotion of top of the range affected person care, ASCO works to beat most cancers and create a world the place most cancers is prevented or cured, and each survivor is wholesome. Conquer Cancer^®, the ASCO Foundation, helps ASCO by funding groundbreaking analysis and training throughout most cancers’s full continuum. Learn extra at www.ASCO.org, and comply with us on Facebook, X, LinkedIn, Instagram, Bluesky, and YouTube.